# Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

> **NCT02717949** · PHASE4 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Liver Disease

## Interventions

- **DRUG:** sofosbuvir/ledipasvir
- **DRUG:** sofosbuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02717949
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-25
- **Primary completion:** 2017-06-05
- **Final completion:** 2017-07-18
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** failure to recruit
- **Last updated:** 2019-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717949, "Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02717949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*